MammaPrint® Reimbursement Indication Extended in Belgium

Contributed by: Business Wire

Logo

Images

(Graphic: Business Wire)

Business Wire embedded0

Tags

Biotechnology

Health

Genetics

Pharmaceutical

Oncology

Agendia, Inc.

More Like This

(Graphic: Business Wire)

Agendia Announces Publication Validating MammaPrint® Utility in Prediction of Extended Endocrine Therapy Benefit

Agendia Achieves CE-IVDR Certification for its MammaPrint® and BluePrint® Breast Cancer Assays

Personalized biology-based insights (Graphic: Business Wire)

Agendia, Inc. Provides Review of Successful 2024

First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer

The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences’ Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

REVEAL GENOMICS® HER2DX® Genomic Test to Be Validated in Pivotal ECOG-ACRIN CompassHER2 pCR Trial in HER2+ Breast Cancer

PR Newswire associated0

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients